Comparative Effects on Fetal Hematopoiesis and Placental Inflammation From Mesenchymal and Hematopoietic Stem Cells as Agents of Transamniotic Stem Cell Therapy (TRASCET) in a Syngeneic Model of Intrauterine Growth Restriction.

Autor: Moskowitzova K; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA., Naus AE; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA., Kycia I; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA., Dang TT; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA., Shroff YV; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA., Bletsas E; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA., Mullin K; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA., Zurakowski D; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA., Fauza DO; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA. Electronic address: dario.fauza@childrens.harvard.edu.
Jazyk: angličtina
Zdroj: Journal of pediatric surgery [J Pediatr Surg] 2024 Jul; Vol. 59 (7), pp. 1277-1281. Date of Electronic Publication: 2024 Mar 15.
DOI: 10.1016/j.jpedsurg.2024.03.011
Abstrakt: Purpose: We compared transamniotic stem cell therapy (TRASCET) using either mesenchymal (MSCs) or hematopoietic (HSCs) stem cells on fetal hematopoiesis in a syngeneic model of intrauterine growth restriction (IUGR).
Methods: Lewis dams exposed to cycling hypoxia (10.5% O 2 ) in late gestation had their fetuses (n = 83) either receiving no intervention (untreated; n = 9), or intra-amniotic injections of either HSCs (HSC; n = 34), MSCs primed to an enhanced anti-inflammatory phenotype (primed-MSC; n = 28), or saline (sham; n = 12). Normal controls (n = 18) were also studied. Complete peripheral blood counts and placental ELISA for inflammation and angiogenesis markers were performed at term.
Results: Overall survival from hypoxia was 41% (34/83). Red blood count (RBC), hematocrit (Hct) and hemoglobin levels (Hb) were all significantly decreased from normal in all hypoxia groups. TRASCET with primed-MSC had significantly higher RBC, Hct, and Hb levels than sham (p = 0.01-0.03, pairwise), though not than untreated (which had no surgical blood loss). The HSC group had only significantly higher Hb levels than sham (p = 0.005). TRASCET with primed-MSC had significantly lower levels of placental TNF-α than sham (p = 0.04), but not untreated.
Conclusions: MCSs seem more effective than HSCs in enhancing hematopoiesis when used as donor cells for TRASCET in a syngeneic model of IUGR.
Level of Evidence: N/A (animal and laboratory study).
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: